Regeneron: Antibody cocktail helps prevent symptomatic COVID-19
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2 by 81% in a phase 3 clinical trial conducted with the National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals announced yesterday.
The Food and Drug Administration has authorized emergency use of the therapy for people at high risk of progressing to severe COVID-19 or hospitalization. The company plans to ask the agency to expand the EUA to include COVID-19 prevention.
Related News Articles
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…